Mary Beth Maloney

Partner, New York

+1 212.351.2315

Mary Beth Maloney is a partner in the New York office, and a member of the Litigation, Life Sciences, Securities Litigation, and Business Restructuring Practice Groups. She serves as the Co-Chair of Hiring for the New York office. Ranked by Chambers USA in its New York Securities Litigation category and recognized by The Best Lawyers in America® for Commercial Litigation, her securities and commercial disputes practice includes first-chair representation of investment funds and advisors in commercial litigation and government investigations, life sciences clients in multi-million-dollar licensing and other contract disputes, as well as companies, boards, and executives in contract and shareholder disputes. She has also defended numerous clients in securities-related civil class actions as well as advised on responding to investigations and enforcement actions by various government agencies, including the Securities and Exchange Commission.

View Full Profile

Tariffs and Royalties in License Agreements: Key Considerations for Life Science Companies

April 14, 2025 | Posted by Karen A. Spindler; Mary Beth Maloney; Topic(s): International Trade; Royalty Finance

Recent shifts in international trade policies have led to the imposition of new tariffs prompting life science companies to reassess their license agreements to understand the potential impact of these new tariffs on royalty calculations under such agreements.

Introducing Biotech Briefings

March 3, 2025 | Posted by Branden C. Berns; Aaron K. Briggs; Jane M. Love, Ph.D.; Mary Beth Maloney; Ryan A. Murr; Melanie E. Neary; John D.W. Partridge; Karen A. Spindler; Eric J. Stock; Todd J. Trattner; Stephen Weissman; Topic(s): Trends and Insights

Dear friends and colleagues,

We are excited to introduce Biotech Briefings, providing Gibson Dunn’s commentary and perspectives on the legal, business, and regulatory issues shaping the life sciences industry.

From groundbreaking developments in biopharma, medical devices, and diagnostics to the evolving landscape of IP, FDA and SEC regulation, Biotech Briefings delivers timely insights for companies, investors, and industry stakeholders.

Stay tuned for expert analysis on:

Key FDA, FTC & SEC developments
M&A, financing & strategic partnerships
Market dynamics shaping investment & innovation

We invite you to follow along for actionable insights at the crossroads of law, business, and science.

The Gibson Dunn Life Sciences Team